Clinical Trials
45 trialsRuxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Big Ten Cancer Research Consortium
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
FORUM2
Bambino Gesù Hospital and Research Institute
Amping up With PemJAK
Columbia University
REACH 5
Novartis
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Incyte Corporation
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
PTCyRuxo
St. Petersburg State Pavlov Medical University
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Memorial Sloan Kettering Cancer Center
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
2002
Xenikos
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Chang Gung Memorial Hospital
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
University of Nebraska
Ruxolitinib for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
RUE-DDGP
Zhengzhou University
Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
JAK2
Samsung Medical Center
HIJAK
The Lymphoma Academic Research Organisation
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
Sichuan University
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Sunnybrook Health Sciences Centre
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Sunnybrook Health Sciences Centre
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group